Five years after starting a three-year exercise program, 80.3% of colon cancer patients were still cancer-free. Among patients handed health-education booklets instead, 73.9% were (Trial). A coin flip decided who got the program. That makes CHALLENGE the first trial of its kind to tie exercise and cancer survival together. Two limits matter from the first line. This was colon cancer, not cancer in general. The program came on top of surgery and chemotherapy, never in place of them.
What the CHALLENGE Trial Tested
The trial is called CHALLENGE. The Canadian Cancer Trials Group ran it at 55 centers from 2009 to 2024. It enrolled 889 people whose colon cancer had been removed by surgery (Trial). All had finished chemotherapy, and none showed any sign of cancer at the start. Most had stage III disease: 802 of the 889, against 87 with high-risk stage II (Registry record). People with rectal cancer could not take part.
A coin flip decided the rest, which is all “randomized” means. Of the 889 people, 445 were assigned a three-year structured exercise program. The other 444 got health-education materials: booklets about activity and good nutrition (Guideline). Notice what the comparison was. The control group was not told to sit still. Both groups got the same booklets, and one group got the program on top.
Researchers then followed everyone for about eight years (Trial). The main measure was disease-free survival: still alive, with no cancer back and no new cancer. At five years, 80.3% of the exercise group met that bar, against 73.9% of the health-education group. The gap works out at about 6 people in every 100.
Survival from any cause pointed the same way. At eight years, 90.3% of the exercise group were alive, against 83.2% of the comparison group. The trial’s authors word this result carefully. Survival from any cause was not the main question the study was built to answer. Read it as supportive rather than settled.
Why does a coin flip matter so much here? Decades of research had already linked activity with better cancer outcomes. But those studies only watched what people chose to do, so they cannot separate two very different stories. People who exercise after a diagnosis may live longer because of the exercise. Or they may exercise because they were doing better to begin with. Handing out the program at random breaks that knot. Before CHALLENGE, the authors note, this kind of evidence simply did not exist (Trial).
What Structured Really Meant
This is the part worth copying, and it is duller than you would expect.
“Structured” had two halves. The first was a person. Every participant got a certified physical activity consultant for three years. The meetings were required, not optional (Guideline). The schedule tapered off over time. There were 12 meetings in the first six months, one every two weeks. Another 12 followed at that same pace through the rest of year one. Then came 24 monthly meetings across years two and three (Trial). That is 48 required check-ins with the same coach.
The second half was a weekly activity target, and it is smaller than most people guess. Participants were asked to add about 10 MET-hours of aerobic exercise a week, on top of whatever they already did. In plain terms, it is roughly two and a half hours of moderate movement a week (Protocol). The trial’s own translation is friendlier still: about 45 to 60 minutes of brisk walking, three or four times a week (Guideline).
Nobody was handed a prescribed workout. Participants chose the type, the pace and the length of their sessions. Brisk walking was the reference activity (Trial). Supervised sessions did exist: 12 in the first six months, paired with the coaching visits, and only recommended after that (Protocol). There was no heart-rate zone to hit and no lactate test to pass.
Did people actually do it? Mostly. Across the full three years, the exercise group raised its activity by about 10 MET-hours a week, hitting the goal (Trial). The honest wrinkle is the comparison group, who drifted upward too. The real gap between the groups was closer to half or two thirds of the target. A one-year report found the same pattern in what people said they did. The exercise group also walked further, rose from a chair more easily and moved better (Trial).
Attendance faded, as attendance does. In the first six months, people showed up for 83% of the required coaching sessions. By years two and three, that had fallen to 63% (Trial). The benefit showed up anyway.
Why Exercise May Slow Cancer
One disclaimer covers this whole section. CHALLENGE measured survival, not biology. It reported no blood markers, no immune cell counts and no tumor samples. Blood was banked for later work on how this might happen (Trial). Every explanation below comes from other, smaller studies.
The most-studied idea involves insulin and a related growth signal called IGF-1. Both can push cells to grow, and regular exercise nudges them down. One pool of 74 trials in people with cancer found a small but real drop in fasting insulin (Meta-analysis). In the same pool, the best IGF-1 results came with harder aerobic work. But that pattern came from sorting the trials afterwards, not from testing easy against hard head to head.
Chronic inflammation is the second candidate. It is a reasonable theory with thin human support. In that same pool of trials, a key inflammation marker barely moved. That change was small enough that chance could explain it.
The third idea is about the immune system. Natural killer cells hunt damaged cells, and one exercise session pushes them into the bloodstream. In mice, exercise sends them into tumors and slows growth. The first human test ran in 20 men with early prostate cancer. The cells really did move into the blood. They still did not turn up inside tumor tissue (Study). A pool of 13 trials in cancer survivors found no consistent change in the number of these cells, or in their killing power (Meta-analysis). Those trials also disagreed sharply with each other. Signals released during exercise, including IL-6 and adrenaline, are the proposed messengers. In humans, that chain is still unproven.
None of this is settled, and none of it has to be. The trial result stands on its own, whichever explanation wins.
The Limits Worth Naming
Start with the disease. This was colon cancer, and 9 in every 10 participants had stage III (Registry record). Rectal cancer was excluded outright. Nothing here tells you what a walking program does for lung, breast or pancreatic cancer.
Next, the sequence. Everyone had already had surgery and finished chemotherapy (Trial). Exercise was tested as an addition to treatment, never as an alternative to one. Nobody should trade a scheduled treatment for a walk.
Then, who got in. Participants had to have finished chemotherapy in the previous two to six months. They had to be well enough to manage daily life, and able to walk for six minutes (Trial). On top of that, they had to be doing less than 150 minutes of moderate activity a week at entry. So the finding applies to people who were unfit but able. The sickest patients were not in this trial, and they might have the most to gain.
Nobody was kept in the dark about their group, either. You cannot hide a coach and a walking plan from a patient. That can shape how people report symptoms, and how closely they stick with care.
And there was a cost. Joint pain, back pain, muscle strains and similar complaints hit 18.5% of the exercise group, against 11.5% of the comparison group (Trial). Two things soften that. Severe cases were rare in both groups, under 1 in 100 (Guideline). And about 1 in 10 of those problems were judged related to the program itself, which works out at under 2 in every 100 people who exercised (Report). It is still a real trade-off, and it is why the slow build matters.
Exercise and Cancer Survival Elsewhere
Outside colon cancer, the evidence is large and consistent, but it is weaker in kind.
The biggest pooled analysis followed 90,844 cancer survivors across six US studies for about 11 years (Cohort study). Survivors who met standard activity guidelines after diagnosis were less likely to die. The pattern held for 10 of 11 cancer types, including bladder, breast and prostate. Ovarian cancer was the one type where the link was too uncertain to call.
That sounds decisive. It is not, for the reason already named. These people chose to exercise. Feeling well makes exercise possible, and being well makes survival more likely. Researchers tested this by throwing out deaths in the first two years, and most of the links survived. That narrows the problem without removing it.
Expert panels have graded the same evidence carefully. One review covered 16 studies and 82,220 colorectal cancer patients. The Global Cancer Update Programme called activity after diagnosis “limited-suggestive”, a step below established (Systematic review). The pooled numbers looked good. Among the most active survivors, the risk of dying was about a third lower (Systematic review). The risk of the cancer returning, or of dying, was about a fifth lower. Almost all of that came from watching people rather than flipping coins. So the panel asked for proper trials anyway.
Very few big trials have put survival itself at the center of an exercise question. INTERVAL-GAP4 tested hard exercise in men with advanced prostate cancer. It closed early because it could not recruit, signing up 145 men of a planned 866 (Trial). So CHALLENGE has this question largely to itself for now.
Benefits during treatment are better studied, though still not settled. One pool of 15 trials covered 1,124 patients. In them, exercise appeared to ease the numbness, tingling and pain of nerve damage from chemotherapy, and to help balance (Meta-analysis). Read that as early evidence. The authors rated their own evidence low quality. Each result rests on only three to seven of those trials. The symptom benefit also shrank by about half once two odd trials were dropped. For cancer-related fatigue, a review of 113 studies and 11,525 people found that exercise helped, and so did talk-based therapy (Meta-analysis). The drugs tested did not show that benefit. The authors recommend either exercise or therapy as a first choice, without ranking them. Not everything works. One trial tested whether exercise and diet help people finish chemotherapy on schedule, and found no difference between the groups (Trial).
It helps to keep these questions apart. Asking how much walking is linked to a longer life is one question. Asking whether movement changes a disease already diagnosed is another. The second claim needs a higher bar. CHALLENGE is the first time it has been cleared.
How to Copy the Program
The dose first. Add about two and a half hours of brisk walking a week, on top of your current routine (Protocol). Split it over three or four sessions. “Brisk” means you can talk but not sing. Adding is the operative word. The trial measured an increase from each person’s own starting point.
Build up slowly. The injury signal was real, and most of it landed on joints and muscles. Start at 15 minutes and add a few minutes each week. That gets you to the target within a couple of months, which is fine.
Then replace the coach, because that was the structural part. Those 48 required appointments turned an intention into three years of walking. A physiotherapist works. So does a cancer rehab program, a referral to an exercise specialist, or a standing weekly walk with someone who notices when you skip. Make it an appointment, not a plan.
Clear it with your oncology team first. This matters more with nerve damage in the feet, a stoma, a recent operation, or treatment still running. Guidelines are on your side: ASCO advises doctors to recommend regular aerobic and strength exercise during treatment meant to cure (Guideline). An international expert panel suggests a workable starting dose. That is 30 minutes of moderate aerobic exercise, three times a week, for 8 to 12 weeks. Strength work twice a week goes alongside it (Consensus statement).
Expect to raise the subject yourself. Only about 15% of patients recall ever being referred to exercise by their oncologist (Report). When one clinic built the referral into its normal workflow, 45% of the patients it screened accepted one. The gap sits in the system, not in the patients.
Frequently Asked Questions
What Is the Link Between Exercise and Cancer Survival?
In one trial, yes. It enrolled 889 people treated for colon cancer, and a coin flip decided who exercised. A three-year structured exercise program left 80.3% cancer-free at five years. Among those handed health-education materials, 73.9% were (Trial). That is one trial in one cancer. For other cancers, exercise and cancer survival are linked in studies that only watched people, and no trial has proven it yet.
Can Exercise Replace Chemotherapy?
No. Everyone in the trial had already had surgery and finished chemotherapy before the program started (Trial). Exercise was tested as something added to standard treatment, never as a substitute for it. Swapping a prescribed treatment for exercise is not supported by any of this evidence.
How Much Exercise Did the Colon Cancer Trial Require?
The target was an extra two and a half hours of moderate aerobic activity a week, on top of existing habits (Protocol). The trial describes that as roughly 45 to 60 minutes of brisk walking, three or four times a week (Guideline). Participants picked their own activity, and walking was the reference.
Does Exercise Help During Chemotherapy?
It may help with how treatment feels. Pooled trials suggest exercise eases cancer-related fatigue, as talk-based therapy does (Meta-analysis). The drugs tested did not show that benefit. Exercise may also ease the numbness and tingling of nerve damage from chemotherapy (Meta-analysis). That evidence is early, and its own authors rated it low quality. One trial found it did not help people finish chemotherapy on schedule (Trial).
Is It Safe to Exercise After Cancer Surgery?
Generally yes, with clearance from your team. Joint and muscle complaints were more common in the exercise group, 18.5% against 11.5% (Trial), though severe cases stayed rare (Guideline). Ask before starting, especially after recent surgery or with an ostomy.
Key Takeaways
- The first coin-flip evidence. CHALLENGE is the first big trial to show an exercise program improving cancer survival: 80.3% cancer-free at five years against 73.9% (Trial).
- The dose is a walk. About 45 to 60 minutes of brisk walking, three or four times a week, added to what you already do (Guideline).
- The coach was the structure. 48 required sessions with an activity consultant over three years, tapering from every two weeks to monthly (Trial).
- An addition, never a replacement. Every participant had already completed surgery and chemotherapy (Trial).
- There is a trade-off. Joint and muscle problems hit 18.5% of the exercise group, against 11.5% of the comparison group (Trial).
- One cancer, one trial. Evidence in other cancers mostly comes from watching people, and panels grade it suggestive, not established (Systematic review).
Movement on the Treatment Plan
Something changed in 2025. A walk stopped being a wellness suggestion tacked on after treatment. A trial now says it belongs on the plan itself. That is a different conversation to have with an oncologist, and a fair one to start.
If you have a diagnosis, ask about an exercise referral by name. If you do not, build the habit now. It is far easier to keep a habit than to start one.
The evidence here is real and still early: one trial, one cancer, one honest result. That is enough to act on, and worth watching as more trials report.
This article is for educational purposes and is not medical advice. Talk to a qualified clinician before changing your health regimen.
Leave a comment